Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 682 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HER2 Negative Breast Carcinoma Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Onvansertib + Paclitaxel In TNBC

NCT05383196
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
Onvansertib, Paclitaxel
Drug
Lead sponsor
Antonio Giordano, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

NCT02048059
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
ANG1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 15, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

NCT01368263
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
goserelin acetate, letrozole, anastrozole, chemotherapy, Surgery
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 15, 2026, 5:33 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Placebo, Palbociclib, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Beverly Hills, California • Boston, Massachusetts • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Active, not recruiting Phase 3 Interventional

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Not listed Phase 1Phase 2 Interventional

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

NCT04669587
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
ZB716, Palbociclib
Drug
Lead sponsor
EnhancedBio USA Inc.
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

NCT00630032
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone
Drug
Lead sponsor
UNICANCER
Other
Eligibility
18 Years and older · Female only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
17
States / cities
Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

NCT03477396
View directory record Official record
Conditions
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Aromatase Inhibitor, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration, Ribociclib
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
70 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
9
States / cities
Corona, California • Duarte, California • Lancaster, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 15, 2026, 5:33 AM EDT
Active, not recruiting Phase 1 Interventional Results available

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

NCT04288089
View directory record Official record
Conditions
Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
Interventions
Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Sarasota, Florida • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

NCT01610284
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
61
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Eribulin in HER2 Negative Metastatic BrCa

NCT01827787
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Milford, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 15, 2026, 5:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

NCT00726180
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab (Herceptin®)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Oct 15, 2026, 5:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

NCT03301350
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Active, not recruiting Phase 1 Interventional

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

NCT01251874
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography, Veliparib
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
3
States / cities
The Bronx, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Recruiting Phase 2 Interventional

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

NCT06361940
View directory record Official record
Conditions
Breast Cancer
Interventions
Aromatase inhibitors or tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 15, 2026, 5:33 AM EDT
Recruiting Phase 2 Interventional

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT07222215
View directory record Official record
Conditions
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2- Breast Cancer, ESR1 Gene Mutation, ER Wildtype, Breast Neoplasms
Interventions
Capecitabine, Elacestrant
Drug
Lead sponsor
Kristina A. Fanucci
Other
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Terminated Phase 1 Interventional

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 5:33 AM EDT
Not listed Phase 2 Interventional

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10Mg Tab
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 15, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

NCT00542191
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin, Definitive Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

NCT01038804
View directory record Official record
Conditions
Breast Cancer
Interventions
YM155, Docetaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Pleasant Hill, California • Lakeland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 15, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

NCT02892734
View directory record Official record
Conditions
HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer, Stage IV Inflammatory Breast Carcinoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

NCT01958021
View directory record Official record
Conditions
Advanced, Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
73
States / cities
Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 15, 2026, 5:33 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Placebo, CDK4/6i, Letrozole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
62
States / cities
Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 5:33 AM EDT